Universal Genetic Testing for Newly Diagnosed Invasive Breast Cancer
In this cross-sectional universal genetic testing study of women with newly diagnosed invasive breast cancer, the prevalence of GPVs was 7.3%, with 5.3% of patients testing positive for B1B2P2. Among B1B2P2-women women, one-third were eligible for PARP inhibitors.
Authors
- Nancy Hamel
- Kristen Mohler
- Stephanie M. Wong (ORCID: https://orcid.org/0000-0002-6850-2192)
- Adrienne Atayan
- Nicholas Meti (ORCID: https://orcid.org/0000-0001-8454-8484)
- Sarkis Meterissian (ORCID: https://orcid.org/0000-0002-9586-3583)
- Zhen Shen (ORCID: https://orcid.org/0000-0002-6109-9775)
- William D. Foulkes (ORCID: https://orcid.org/0000-0001-7427-4651)
- Daniel E. Jimenez (ORCID: https://orcid.org/0000-0003-2135-0619)
- David Szlachtycz
- Ipshita Prakash (ORCID: https://orcid.org/0000-0002-0730-5363)
- Mark Basik (ORCID: https://orcid.org/0000-0002-2633-5410)
- Stephanie Totten
- David Fleiszer (ORCID: https://orcid.org/0000-0003-3561-3731)
- Zoulikha Rezoug (ORCID: https://orcid.org/0009-0000-2490-7967)
- Khashayar Esfahani (ORCID: https://orcid.org/0000-0003-2221-3755)
- Brianna Lemieux Anglin
- Sophie Albert
- D. L. Anderson (ORCID: https://orcid.org/0000-0002-4328-0386)
- Francine Tremblay (ORCID: https://orcid.org/0000-0003-4497-7748)
- Jean-François Boileau
- George Chong
- Leila Feng
Institutions
- McGill University Health Centre (CA)
- Jewish General Hospital (CA)
- St Mary's Hospital Centre (CA)
- McGill University (CA)
- Qatar University (QA)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2024-09-03
- DOI
- https://doi.org/10.1001/jamanetworkopen.2024.31427
- Citations
- 16
- Primary Topic
- BRCA gene mutations in cancer
- Type
- article
- Field-Weighted Citation Impact
- 8.81
Funders
- Bristol-Myers Squibb
- AstraZeneca
- Fondation du cancer du sein du Québec
- Jewish General Hospital
- Fondation de l'Hôpital général juif